Nuvalent Inc

GSK is targeting more than £40 billion in sales, above the £36.4 billion consensus estimate, with oncology assets driving much of the potential upside, Chief Financial Officer Julie Brown said in a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day. Brown said the largest difference between GSK's outlook and consensus lies in oncology, citing the antibody-drug conjugate portfolio including assets referred to as MORES and RISRES, as well as BLENREP and Jemperli. The company's simplification program is expected to generate £1.9 billion in savings, with most of the savings intended to fund pipeline investment and support margins through upcoming patent expirations for dolutegravir-based HIV medicines; GSK expects margins to be stable to improving from 2028 through 2030. GSK's strategic portfolio review identified seven major assets across roughly 18 indications for accelerated development, and specialty products, which accounted for just over 40% of the business compared with roughly one-third when Brown joined in early 2023, are expected to exceed 50% by 2031. Key growth opportunities include the launches of Excentia, BLENREP, bepirovirsen and Nuvalent-derived medicines, while TRELEGY pricing pressure under the Inflation Reduction Act and tougher SHINGRIX comparisons are expected to weigh on 2027 performance.

British pharmaceutical giant GSK announced that its first lung cancer drug, Jiditro, has received marketing approval from the US Food and Drug Administration. The approval came ahead of the original review deadline, allowing GSK to enter the highly profitable lung cancer treatment market. Jiditro was acquired from the US biopharmaceutical company Newvalent, which GSK bought for 10.6 billion dollars about two months ago. It has been approved for patients with previously treated ROS1-positive non-small cell lung cancer. In early to mid-stage clinical trials, tumors shrank or disappeared in 44 percent of 117 patients, and among those who responded, 82 percent maintained their response at six months and 69 percent at twelve months. With this approval, GSK aims to accelerate the turnaround of its oncology business under new CEO Luke Miles and achieve its target of over 40 billion pounds in revenue by 2031.

US biotech and pharmaceutical IPOs have delivered a weighted average return of 55% this year, far outpacing the broader US IPO market's 4.4% weighted average loss, according to Bloomberg data. At least six biotechs, led by CRISPR-based genetic medicines developer Scribe Therapeutics Inc., have filed for IPOs this month that could price later in July and the first half of August. The sector's outperformance is driven by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory backdrop, notable trial data breakthroughs, and big pharma acquisitions, including Abbvie Inc.'s purchase of Apogee Therapeutics Inc., GSK Plc's deal for Nuvalent Inc., and Vertex Pharmaceuticals Inc.'s purchase of Crinetics Pharmaceuticals Inc. Proceeds from biotech IPOs this year have topped $5 billion, three times last year's total, and include the biggest-ever biotech listing, Parabilis Medicines Inc.'s $770.6 million offering. Pattern hair loss drug company Veradermics Inc. is up over 500% since its February debut, making it the best performing US IPO from any sector this year.

GSK announced that its indirect wholly owned subsidiary, Harmony Row Acquisition Co., has formally launched a tender offer to acquire all outstanding Class A and Class B common shares of Nuvalent for $124.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement signed on June 9, 2026, and represents the next step toward completing the planned acquisition. The tender offer is subject to applicable withholding taxes and the conditions outlined in the offer documents.

Biopharma executives' confidence in the industry has reached its highest point in four years, with 55% of surveyed professionals feeling optimistic or very optimistic about growth over the next 12 months, up from 46% in 2023, according to GlobalData's State of the Biopharmaceutical Industry 2026 mid-year update. The survey of 157 pharmaceutical professionals found that 69% of respondents highlighted US tariffs and government actions as the biggest policy concern, a figure that rose to 78% among European respondents. Deal activity has surged, with first-quarter 2026 M&A deal value rising 71% year over year and life sciences and pharma deals surpassing $65 billion, the strongest quarter since 2020. Notable transactions include Eli Lilly's acquisition of 10 companies this year, led by a $7.8 billion deal for Centessa, while the second quarter saw Sun Pharma's $11.75 billion takeover of Organon and GSK's $10.6 billion acquisition of Nuvalent. The IPO market has also resurged, with activity up 210%, and Parabilis Medicines set a new biotech IPO record with a $670 million Nasdaq listing just two months after Kailera Therapeutics raised $625 million.

PwC reports that US pharma and life sciences deal value surpassed $65 billion in the first quarter of 2026, the strongest quarter since pandemic-related highs in 2020. The surge is driven by the largest patent cliff in industry history, with more than $300 billion in branded pharma revenue exposed, forcing companies to pursue acquisitions in areas like GLP-1 receptor agonists, RNA therapeutics, and antibody-drug conjugates. Eli Lilly has been the most active buyer, purchasing 10 companies this year including a $7.8 billion deal for Centessa. The momentum continued into the second quarter with Sun Pharma's $11.75 billion takeover of Organon and GSK's $10.6 billion acquisition of Nuvalent. PwC expects M&A to remain strong through year-end as large-cap pharma fills loss-of-exclusivity gaps, while a resurgent IPO market saw Parabilis Medicines raise a record $670 million in the largest biotech IPO ever.